Oxymorphone
- Generic Name
- Oxymorphone
- Brand Names
- Opana
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19NO4
- CAS Number
- 76-41-5
- Unique Ingredient Identifier
- 9VXA968E0C
- Background
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
- Indication
For the treatment of moderate-to-severe pain.
- Associated Conditions
- Anxiety, Severe Pain, Moderate Pain
- Associated Therapies
- Perioperative analgesia, Obstetrical analgesia therapy
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 12
- Registration Number
- NCT00580294
- Locations
- ๐บ๐ธ
Icahn School of Medcine at Mount Sinai, New York, New York, United States
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
- Conditions
- Acute Pain
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT00226395
- Locations
- ๐บ๐ธ
Univ. Pittsburgh Hospital, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniv. Pittsburgh Medical center, Pittsburgh, Pennsylvania, United States
๐บ๐ธHuntington Memorial Hospital, Pasadena, California, United States
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
- Conditions
- Chronic Pain
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00226421
- Locations
- ๐บ๐ธ
Mid-America Physiatrists, Overland Park, Kansas, United States
๐บ๐ธOcala Rheumatology Research Center, Ocala, Florida, United States
๐บ๐ธFeasterville Family Health Center, Feasterville, Pennsylvania, United States
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
- Conditions
- Chronic Pain
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00225797
- Locations
- ๐บ๐ธ
Mid-America Physiatrists, Overland Park, Kansas, United States
๐บ๐ธThe Arthritis Center, Palm Harbor, Florida, United States
๐บ๐ธNew England Research, Bridgeport, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.